Ocrelizumab in relapsing-remitting multiple sclerosis: 72-week efficacy and safety results of a phase II, randomised, placebo-controlled, multi-centre trial

被引：0
|
作者：
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Yin, M.
Leppert, D.
Glanzman, R.
Tinbergen, J.
Hauser, S.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Univ Toronto, Toronto, ON, Canada
[5] McGill Univ, Montreal, PQ, Canada
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [1] Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial
    Kappos, Ludwig
    Li, David
    Calabresi, Peter
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Tinbergen, Jeroen
    Hauser, Stephen
    [J]. NEUROLOGY, 2011, 76 (09) : A545 - A545
  • [2] Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial
    Zhao, Y.
    Li, D. K. B.
    Riddehough, A.
    Traboulsee, A.
    Masterman, D.
    Gilberg, F.
    Kappos, L.
    Leppert, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 446 - 447
  • [3] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Yin, M.
    Leppert, D.
    Glanzmann, R.
    Tinbergen, J.
    Hauser, S. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S194 - S195
  • [4] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    Kappos, Ludwig
    Li, David
    Calabresi, Peter A.
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Tinbergen, Jeroen
    Hauser, Stephen L.
    [J]. LANCET, 2011, 378 (9805): : 1779 - 1787
  • [5] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Wells, C.
    Leppert, D.
    Masterman, D.
    Tinbergen, J.
    Hauser, S. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 140 - 141
  • [6] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: Week 144 results of a Phase II, randomised, multicentre trial
    Kappos, L.
    Bar-Or, A.
    Sauter, A.
    Leppert, D.
    Li, D.
    Masterman, D.
    Barkhof, F.
    Tinbergen, J.
    O'Connor, P.
    Calabresi, P. A.
    Hauser, S. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1875 - 1875
  • [7] Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
    Hauser, Stephen
    Li, David
    Calabresi, Peter
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Sauter, Annette
    Leppert, David
    Masterman, Donna
    Tinbergen, Jeroen
    Kappos, Ludwig
    [J]. NEUROLOGY, 2013, 80
  • [8] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
    Bar-Or, Amit
    Calabresi, Peter A. J.
    Arnlod, Douglas
    Markowitz, Clyde
    Shafer, Stuart
    Kasper, Lloyd H.
    Waubant, Ernmanuelle
    Gazda, Suzanne
    Fox, Robert J.
    Panzara, Michael
    Sarkar, Neena
    Agarwal, Sunil
    Smith, Craig H.
    [J]. ANNALS OF NEUROLOGY, 2008, 63 (03) : 395 - 400
  • [9] Safety and efficacy of rituximab in adults with relapsing-remitting multiple sclerosis: results of a phase II placebo-controlled, multicentre trial through 48 weeks
    Waubant, E.
    Hauser, S.
    Amold, D. L.
    Vollmer, T.
    Antel, J. P.
    Fox, R.
    Bar-Or, A.
    Panzara, M.
    Sarkar, N.
    Agarwal, S.
    Langer-Gould, A.
    Smith, C.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 : S165 - S165
  • [10] Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Wells, C.
    Leppert, D.
    Glanzman, R.
    Tinbergen, J.
    Hauser, S.
    [J]. JOURNAL OF NEUROLOGY, 2012, 259 : S65 - S65
12345